Loading clinical trials...
Loading clinical trials...
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Conditions
Interventions
Donanemab
Placebo
Locations
274
United States
Gilbert Neurology
Gilbert, Arizona, United States
Xenoscience
Phoenix, Arizona, United States
Banner Alzheimer's Institute
Phoenix, Arizona, United States
Perseverance Research Center
Scottsdale, Arizona, United States
Banner Sun Health Research Institute
Sun City, Arizona, United States
Banner Alzheimer's Institute Tucson
Tucson, Arizona, United States
Start Date
June 19, 2020
Primary Completion Date
April 14, 2023
Completion Date
November 1, 2028
Last Updated
August 29, 2025
NCT07545473
NCT04570085
NCT07531732
NCT07290387
NCT06501495
NCT06121544
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions